Patents by Inventor Michael Van Zandt

Michael Van Zandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20190054101
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20180346489
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: August 10, 2018
    Publication date: December 6, 2018
    Inventors: Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
  • Arginase inhibitors as therapeutics
    Patent number: 10098902
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 16, 2018
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20180251479
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 6, 2018
    Inventors: Michael Van Zandt, Adam Golebiowski, Min K. Ji, Darren Whitehouse, Todd Ryder, Raymond P. Beckett
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10065974
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20180222926
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 9, 2018
    Inventors: Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, Jr, Lene Raunkjaer PETERSEN, Francesco PARLATI, Matthew I. GROSS
  • Inhibitors of arginase and their therapeutic applications
    Patent number: 9994594
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 12, 2018
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20170183362
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 29, 2017
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
    Publication number: 20170121352
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20170000808
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 5, 2017
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Arginase inhibitors as therapeutics
    Patent number: 9440995
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 13, 2016
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Inhibitors of arginase and their therapeutic applications
    Patent number: 9266908
    Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: February 23, 2016
    Assignee: MARS, INCORPORATED
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • Arginase inhibitors as therapeutics
    Patent number: 9233985
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: January 12, 2016
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar Erik Jagdmann, Jr.
  • Ring constrained analogs as arginase inhibitors
    Patent number: 9200011
    Abstract: The inventive boronic acid analogs are potent inhibitors of Arginase I and II activity. These compounds are candidate therapeutics for treating a disease or disorder associated with an imbalance in the activity or concentration of cellular arginase I and arginase II enzymes. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the compositions for therapy.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 1, 2015
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Gunnar Erik Jagdmann, Jr.
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20150191492
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: February 4, 2015
    Publication date: July 9, 2015
    Inventors: Michael Van Zandt, Gunnar E. Jagdmann
  • Inhibitors of arginase and their therapeutic applications
    Patent number: 9040703
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: May 26, 2015
    Assignee: Mars, Incorporated
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Paul Beckett
  • RING CONSTRAINED ANALOGS AS ARGINASE INHIBITORS
    Publication number: 20150080341
    Abstract: The inventive boronic acid analogs are potent inhibitors of Arginase I and II activity. These compounds are candidate therapeutics for treating a disease or disorder associated with an imbalance in the activity or concentration of cellular arginase I and arginase II enzymes. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the compositions for therapy.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Michael Van Zandt, Gunnar Erik Jagdmann, JR.
  • INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20140371175
    Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20140343019
    Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 20, 2014
    Inventors: Michael Van Zandt, Adam Golebiowski, Min Koo Ji, Darren Whitehouse, Todd Ryder, Raymond Paul Beckett
  • ARGINASE INHIBITORS AS THERAPEUTICS
    Publication number: 20120129806
    Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.
    Type: Application
    Filed: October 19, 2011
    Publication date: May 24, 2012
    Inventors: Michael Van Zandt, Gunnar Erik Jagdmann, JR.